Pharmacokinetics and Safety of XAV-19, a Swine Glyco-humanized Polyclonal Anti-SARS-CoV-2 Antibody, for COVID-19-Related Moderate Pneumonia: a Randomized, Double-Blind, Placebo-Controlled, Phase IIa Study.
COVID-19
XAV-19
phase IIa
pneumonia
polyclonal glyco-humanized anti-SARS-CoV-2 antibody
Journal
Antimicrobial agents and chemotherapy
ISSN: 1098-6596
Titre abrégé: Antimicrob Agents Chemother
Pays: United States
ID NLM: 0315061
Informations de publication
Date de publication:
17 08 2021
17 08 2021
Historique:
pubmed:
29
6
2021
medline:
24
8
2021
entrez:
28
6
2021
Statut:
ppublish
Résumé
We assessed the pharmacokinetics and safety of XAV-19, a swine glyco-humanized polyclonal antibody against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), in coronavirus disease 2019 (COVID-19)-related moderate pneumonia. The objective was to evaluate the optimal dose and safety of XAV-19 during this first administration to patients with COVID-19-related moderate pneumonia. In this phase IIa trial, adults with COVID-19-related moderate pneumonia with a duration of ≤10 days were randomized to receive an infusion of XAV-19 at 0.5 mg/kg of body weight at day 1 and day 5 (group 1), 2 mg/kg at day 1 and day 5 (group 2), or 2 mg/kg at day 1 (group 3) or placebo. Eighteen patients (
Identifiants
pubmed: 34181475
doi: 10.1128/AAC.01237-21
pmc: PMC8370226
doi:
Banques de données
ClinicalTrials.gov
['NCT04453384']
Types de publication
Clinical Trial, Phase II
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0123721Références
JAMA. 2020 Apr 7;323(13):1239-1242
pubmed: 32091533
N Engl J Med. 2021 Feb 25;384(8):693-704
pubmed: 32678530
Nature. 2021 Mar;591(7848):124-130
pubmed: 33494096
N Engl J Med. 2021 Jan 21;384(3):229-237
pubmed: 33113295
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Immunity. 2021 Apr 13;54(4):797-814.e6
pubmed: 33765436
Lancet Infect Dis. 2020 Oct;20(10):1122-1123
pubmed: 32325035
Eur J Immunol. 2021 Jun;51(6):1412-1422
pubmed: 33576494
N Engl J Med. 2021 Jan 21;384(3):238-251
pubmed: 33332778
Lancet Infect Dis. 2021 Jun;21(6):783-792
pubmed: 33636145
Lancet Infect Dis. 2020 Jun;20(6):697-706
pubmed: 32224310
JAMA. 2021 Apr 27;325(16):1620-1630
pubmed: 33734299
N Engl J Med. 2020 Nov 5;383(19):1813-1826
pubmed: 32445440
Trials. 2021 Mar 9;22(1):199
pubmed: 33750432
Euro Surveill. 2020 Jan;25(3):
pubmed: 31992387
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
Nature. 2020 May;581(7809):465-469
pubmed: 32235945
JAMA. 2021 Feb 16;325(7):632-644
pubmed: 33475701
Intensive Care Med. 2020 May;46(5):846-848
pubmed: 32125452